Unlock stock picks and a broker-level newsfeed that powers Wall Street.
0.7002
-0.0310
(-4.24%)
At close: April 3 at 4:00:01 PM EDT
0.7396
+0.04
+(5.63%)
Pre-Market: 4:01:10 AM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Rene Russo BCPS, Pharm.D. | President, CEO & Director | 875.13k | -- | 1975 |
| Mr. Christopher Frankenfield | Chief Operating Officer | 704.85k | -- | 1982 |
| Dr. Katarina Luptakova M.D. | Chief Medical Officer | 591.92k | -- | 1976 |
| Mr. Kevin M. Brennan | Senior VP of Finance & Accounting | -- | -- | 1970 |
| Dr. Uli Bialucha Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Ms. Caroline Hensley | Chief Legal Officer | -- | -- | -- |
| Dr. Scott Coleman Ph.D. | Chief Development Officer | -- | -- | -- |
Xilio Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 64
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Xilio Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
March 11, 2025 at 11:30 AM UTC
Xilio Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
RLYB Rallybio Corporation
0.5570
-3.97%
INAB IN8bio, Inc.
0.1612
-5.51%
IVVD Invivyd, Inc.
0.5500
-5.03%
AEON AEON Biopharma, Inc.
0.5315
-1.74%
ENTO Entero Therapeutics, Inc.
0.4370
+6.30%
IKNA Ikena Oncology, Inc.
1.2000
-4.00%
CGTX Cognition Therapeutics, Inc.
0.3860
-6.51%
GLUE Monte Rosa Therapeutics, Inc.
3.8900
-11.79%
LIXT Lixte Biotechnology Holdings, Inc.
1.1850
-2.87%
XFOR X4 Pharmaceuticals, Inc.
0.2100
-7.89%